Iovance Biotherapeutics (NASDAQ:IOVA) specializes in pioneering the development of novel cancer immunotherapies. Its primary focus is on T-cell therapy, aiming to harness the power of a patient's immune system to target and eliminate cancer cells. At the forefront of Iovance’s innovative projects is the development of tumor-infiltrating lymphocyte (TIL) technology, which they believe could offer new, effective treatment options for patients with various cancer types, including melanoma, cervical, and head and neck cancers. The company is driven by a commitment to advancing its clinical programs and expanding its pipeline to provide innovative cancer treatments that improve patient outcomes.